BXRX:NSD-Baudax Bio, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.83

Change

-0.05 (-6.22)%

Market Cap

USD 0.06B

Volume

1.30M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-4.60 (-2.82%)

USD65.51B 109.35 N/A
VRTX Vertex Pharmaceuticals Incorpo..

-2.11 (-0.98%)

USD55.66B 20.49 14.38
REGN Regeneron Pharmaceuticals, Inc

+5.59 (+1.13%)

USD52.92B 16.28 12.68
BNTX BioNTech SE

+18.64 (+10.15%)

USD44.37B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+1.38 (+0.81%)

USD37.67B 55.32 39.57
BGNE BeiGene, Ltd

-8.65 (-2.77%)

USD28.69B N/A N/A
SGEN Seagen Inc

-3.56 (-2.55%)

USD25.31B 38.92 34.59
RPRX Royalty Pharma plc

+0.52 (+1.27%)

USD24.87B 22.60 14.92
GMAB Genmab A/S

-0.16 (-0.43%)

USD24.33B 26.59 3.07
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BXRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.12% 33% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.12% 33% F 15% F
Trailing 12 Months  
Capital Gain -72.85% 4% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.85% 4% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -23.15% 9% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.15% 9% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 34.99% 81% B- 50% F
Risk Adjusted Return -66.17% 8% F 4% F
Market Capitalization 0.06B 11% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 96% A 97% A+
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -1.41 14% F 59% F
EV/EBITDA 0.23 65% D 94% A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 498.99% 100% A+ 100% A+
Return on Assets -47.97% 16% F 5% F
Debt to Equity Ratio -57.23% 92% A- 94% A
Technical Ratios  
Short Ratio 2.03 68% D+ 57% F
Short Percent 6.36% 53% F 33% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.